(Q45801403)

16 December 2017

http://europepmc.org/abstract/MED/24748646

title

HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-β therapy in multiple sclerosis (English)

1 reference

16 December 2017

http://europepmc.org/abstract/MED/24748646

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24748646%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Roberto Alvarez-Lafuente

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24748646%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Jordi Rio

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24748646%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Xavier Montalban

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24748646%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Laura Leyva

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24748646%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Elena Urcelay

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24748646%20AND%20SRC:MED&resulttype=core&format=json

Rafael Pelaez Lamamie De Clairac Arroyo

31 May 2020

6

object named as

Rafael Arroyo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24748646%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Manuel Comabella Lopez

11

object named as

Manuel Comabella

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24748646%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

1

Concepción Núñez

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24748646%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Miguel Fernández-Arquero

5

object named as

Miguel Fernández-Arquero

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24748646%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

author name string

Oscar Fernández

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24748646%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Begoña Oliver-Martos

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24748646%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

language of work or name

English

0 references

publication date

19 April 2014

1 reference

16 December 2017

http://europepmc.org/abstract/MED/24748646

published in

Journal of Medical Genetics

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24748646%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

volume

51

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24748646%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24748646%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

page(s)

395-400

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24748646%20AND%20SRC:MED&resulttype=core&format=json

Multiple sclerosis--the plaque and its pathogenesis

31 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2014-102348

Risk alleles for multiple sclerosis identified by a genomewide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2014-102348

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2014-102348

Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2014-102348

Persistency of neutralizing antibodies depends on titer and interferon-beta preparation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2014-102348

Determinants of interferon β efficacy in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2014-102348

Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2014-102348

Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2014-102348

In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2014-102348

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2014-102348

Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2014-102348

The challenge of follow-on biologics for treatment of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2014-102348

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2014-102348

Emerging oral therapies in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2014-102348

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2014-102348

Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2014-102348

Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2014-102348

HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2014-102348

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2014-102348

Neutralizing antibodies to interferon beta in multiple sclerosis: analytical evaluation for validation of a cytopathic effect assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2014-102348

Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2014-102348

Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2014-102348

Polymorphisms of innate pattern recognition receptors, response to interferon-beta and development of neutralizing antibodies in multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2014-102348

Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2014-102348

Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2014-102348

Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon-β therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2014-102348

Biomarkers of treatment response in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2014-102348

Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2014-102348

Neutralizing Antibodies Are Associated with a Reduction of Interferon-^|^beta; Efficacy during the Treatment of Japanese Multiple Sclerosis Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2014-102348

Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon β: Implications for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2014-102348

10.1136/JMEDGENET-2014-102348

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24748646%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

1 reference